Insights from 2023 ASCO® Annual Meeting

 

Insights from 2023 ASCO® Annual Meeting
B

ASCO® 2023 Insights: "Randomized Phase 2 Trial in Metastatic Soft Tissue Sarcoma - Cabozantinib +/- PD-1 and CTLA-4 Inhibition"

By Insights from 2023 ASCO® Annual Meeting FEATURING Brian Van Tine
By Insights from 2023 ASCO® Annual Meeting FEATURING Brian Van Tine
289 views
June 15, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

17:48
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Feat. R. Alter, A. Rezazadeh

Featured Video

20:14
Exelixis

Hypothetical Patient Case: RAI-R Metastatic Differentiated Thyroid C…

Feat. R. Alter, R. Shameem
Sarcoma
12:04

INSIGHT Study - Ripretinib vs. Sunitinib in Patients With Advanced G…

Insights from 2023 ASCO® Annual Meeting

S. George

122 views
07:29

ASCO® 2023 Insights: "Randomized Phase 2 Trial in Metastatic Soft Ti…

Insights from 2023 ASCO® Annual Meeting

B. Van Tine

289 views
21:21

ASCO® 2023 Insights: "Radiation Therapy in Metastatic Sarcoma - Moda…

Insights from 2023 ASCO® Annual Meeting

N. Laack

225 views
12:21

ASCO® 2023 Insights: "A Single-Arm, Open-Label Phase 2 Trial of Doxo…

Insights from 2023 ASCO® Annual Meeting

B. Wilky

120 views
09:02

ASCO® 2023 Insights: "A Phase II Basket Trial of Dual Anti-CTLA-4 an…

Insights from 2023 ASCO® Annual Meeting

Y. Chae

416 views